Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 84

1.

Rituximab and fludarabine or cyclophosphamide combination treatment for older waldenström macroglobulinemia patients.

Xu X, Wang C, Wang Y, Zhou L, Bai H.

Turk J Haematol. 2013 Dec;30(4):422-3. doi: 10.4274/TJH.2013.0030. Epub 2013 Dec 5. No abstract available.

2.

Waldenström macroglobulinemia: my way.

Gertz M.

Leuk Lymphoma. 2013 Mar;54(3):464-71. doi: 10.3109/10428194.2012.717173. Epub 2012 Aug 25. Review.

PMID:
22860921
3.

Fludarabine may overcome resistance to rituximab in IgM-related neuropathy.

Koya J, Iwata A, Nakamura F, Nagashima Y, Ichikawa M, Tsuji S, Kurokawa M.

J Neurol Sci. 2012 Apr 15;315(1-2):150-2. doi: 10.1016/j.jns.2011.12.001. Epub 2012 Jan 10.

PMID:
22236889
4.

Rituximab-induced life-threatening coagulopathy occurring in a patient with Waldenström macroglobulinemia treated with fludarabine, cyclophosphamide, and rituximab combination.

Pilorge S, Park S, Dreyfus F, Bouscary D, Tamburini J.

Leuk Lymphoma. 2010 Dec;51(12):2288-90. doi: 10.3109/10428194.2010.523127. Epub 2010 Oct 7. No abstract available.

PMID:
20929331
5.

[Skin abnormalities as first sign of Waldenström macroglobulinaemia].

Visser MF, Croon-de Boer F, Lonnee ER, Drees A.

Ned Tijdschr Geneeskd. 2010;154:A2097. Dutch.

PMID:
21029489
6.

Fludarabine plus cyclophosphamide and rituximab in Waldenstrom macroglobulinemia: an effective but myelosuppressive regimen to be offered to patients with advanced disease.

Tedeschi A, Benevolo G, Varettoni M, Battista ML, Zinzani PL, Visco C, Meneghini V, Pioltelli P, Sacchi S, Ricci F, Nichelatti M, Zaja F, Lazzarino M, Vitolo U, Morra E.

Cancer. 2012 Jan 15;118(2):434-43. doi: 10.1002/cncr.26303. Epub 2011 Jul 5.

7.

[The treatment of Waldenström macroglobulinemia and the therapy of diseases caused by monoclonal IgM gammaglobulin].

Adam Z, Scudla V, Krejcí M, Korístek Z.

Vnitr Lek. 2008 Jan;54(1):68-83. Review. Czech.

PMID:
18390120
8.

[Effective treatment with rituximab in two patients with Waldenström macroglobulinemia].

Yoshimi A, Arai S, Iijima K, Iki S, Usuki K, Urabe A.

Rinsho Ketsueki. 2005 Oct;46(10):1109-13. Japanese.

PMID:
16440772
9.

Treatment of Waldenstrom's macroglobulinemia with the combination of fludarabine and cyclophosphamide.

Dimopoulos MA, Hamilos G, Efstathiou E, Siapkaras I, Matsouka C, Gika D, Grigoraki V, Papadimitriou C, Mitsibounas D, Anagnostopoulos N.

Leuk Lymphoma. 2003 Jun;44(6):993-6.

PMID:
12854900
10.

Fludarabine, cyclophosphamide and rituximab (FCR) induced pulmonary hypertension in Waldenstrom macroglobulinemia.

Lazarevic VLj, Liljeholm M, Forsberg K, Söderberg S, Wahlin A.

Leuk Lymphoma. 2008 Jun;49(6):1209-11. doi: 10.1080/10428190802007718. No abstract available.

PMID:
18452089
11.

Rituximab-based treatments in Waldenström's macroglobulinemia.

Dimopoulos MA, Kastritis E, Roussou M, Eleutherakis-Papaiakovou E, Migkou M, Gavriatopoulou M, Tassidou A, Terpos E.

Clin Lymphoma Myeloma. 2009 Mar;9(1):59-61. doi: 10.3816/CLM.2009.n.015. Review.

PMID:
19362975
12.

Primary treatment of Waldenström macroglobulinemia with dexamethasone, rituximab, and cyclophosphamide.

Dimopoulos MA, Anagnostopoulos A, Kyrtsonis MC, Zervas K, Tsatalas C, Kokkinis G, Repoussis P, Symeonidis A, Delimpasi S, Katodritou E, Vervessou E, Michali E, Pouli A, Gika D, Vassou A, Terpos E, Anagnostopoulos N, Economopoulos T, Pangalis G.

J Clin Oncol. 2007 Aug 1;25(22):3344-9. Epub 2007 Jun 18.

13.

Fludarabine combination therapy is highly effective in first-line and salvage treatment of patients with Waldenström's macroglobulinemia.

Tam CS, Wolf MM, Westerman D, Januszewicz EH, Prince HM, Seymour JF.

Clin Lymphoma Myeloma. 2005 Sep;6(2):136-9.

PMID:
16231852
14.

Diagnosis and management of Waldenström macroglobulinemia: Mayo stratification of macroglobulinemia and risk-adapted therapy (mSMART) guidelines.

Ansell SM, Kyle RA, Reeder CB, Fonseca R, Mikhael JR, Morice WG, Bergsagel PL, Buadi FK, Colgan JP, Dingli D, Dispenzieri A, Greipp PR, Habermann TM, Hayman SR, Inwards DJ, Johnston PB, Kumar SK, Lacy MQ, Lust JA, Markovic SN, Micallef IN, Nowakowski GS, Porrata LF, Roy V, Russell SJ, Short KE, Stewart AK, Thompson CA, Witzig TE, Zeldenrust SR, Dalton RJ, Rajkumar SV, Gertz MA.

Mayo Clin Proc. 2010 Sep;85(9):824-33. doi: 10.4065/mcp.2010.0304. Epub 2010 Aug 11. Review.

15.

Multicenter, randomized comparative trial of fludarabine and the combination of cyclophosphamide-doxorubicin-prednisone in 92 patients with Waldenström macroglobulinemia in first relapse or with primary refractory disease.

Leblond V, Lévy V, Maloisel F, Cazin B, Fermand JP, Harousseau JL, Remenieras L, Porcher R, Gardembas M, Marit G, Deconinck E, Desablens B, Guilhot F, Philippe G, Stamatoullas A, Guibon O; French Cooperative Group on Chronic Lymphocytic Leukemia and Macroglobulinemia.

Blood. 2001 Nov 1;98(9):2640-4.

16.

Maintenance Rituximab is associated with improved clinical outcome in rituximab naïve patients with Waldenstrom Macroglobulinaemia who respond to a rituximab-containing regimen.

Treon SP, Hanzis C, Manning RJ, Ioakimidis L, Patterson CJ, Hunter ZR, Sheehy P, Turnbull B.

Br J Haematol. 2011 Aug;154(3):357-62. doi: 10.1111/j.1365-2141.2011.08750.x. Epub 2011 May 25.

PMID:
21615385
17.

[Waldemström s macroglobulinemia].

Khosravi Shahi P, del Castillo Rueda A, Díaz Muñoz de la Espada VM.

An Med Interna. 2006 Jun;23(6):291-3. Spanish.

PMID:
17067225
18.

Mechanisms of activity of the TORC1 inhibitor everolimus in Waldenstrom macroglobulinemia.

Roccaro AM, Sacco A, Jia X, Banwait R, Maiso P, Azab F, Flores L, Manier S, Azab AK, Ghobrial IM.

Clin Cancer Res. 2012 Dec 15;18(24):6609-22. doi: 10.1158/1078-0432.CCR-12-1532. Epub 2012 Oct 9.

19.

Waldenström macroglobulinaemia.

Fonseca R, Hayman S.

Br J Haematol. 2007 Sep;138(6):700-20. Epub 2007 Aug 2. Review.

PMID:
17672883
20.

Long-term outcomes to fludarabine and rituximab in Waldenström macroglobulinemia.

Treon SP, Branagan AR, Ioakimidis L, Soumerai JD, Patterson CJ, Turnbull B, Wasi P, Emmanouilides C, Frankel SR, Lister A, Morel P, Matous J, Gregory SA, Kimby E.

Blood. 2009 Apr 16;113(16):3673-8. doi: 10.1182/blood-2008-09-177329. Epub 2008 Nov 17.

Items per page

Supplemental Content

Write to the Help Desk